NO990541L - Krystallinsk form av 4-(5-metyl-3-fenylisoksazol-4-yl)benzensulfonamid - Google Patents

Krystallinsk form av 4-(5-metyl-3-fenylisoksazol-4-yl)benzensulfonamid

Info

Publication number
NO990541L
NO990541L NO990541A NO990541A NO990541L NO 990541 L NO990541 L NO 990541L NO 990541 A NO990541 A NO 990541A NO 990541 A NO990541 A NO 990541A NO 990541 L NO990541 L NO 990541L
Authority
NO
Norway
Prior art keywords
phenylisoxazol
benzenesulfonamide
methyl
crystalline form
crystalline
Prior art date
Application number
NO990541A
Other languages
English (en)
Other versions
NO312461B1 (no
NO990541D0 (no
Inventor
John J Talley
John R Medich
Kathleen T Mclaughlin
Henry T Gaud
Edward E Yonan
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO990541L publication Critical patent/NO990541L/no
Publication of NO990541D0 publication Critical patent/NO990541D0/no
Publication of NO312461B1 publication Critical patent/NO312461B1/no

Links

Classifications

    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W40/00—Arrangements for thermal protection or thermal control
    • H10W40/60—Securing means for detachable heating or cooling arrangements, e.g. clamps
    • H10W40/611—Bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W40/00—Arrangements for thermal protection or thermal control
    • H10W40/70—Fillings or auxiliary members in containers or in encapsulations for thermal protection or control
    • H10W40/73—Fillings or auxiliary members in containers or in encapsulations for thermal protection or control for cooling by change of state

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
NO19990541A 1996-08-14 1999-02-05 Krystallinsk form B av 4-[5-metyl-3-fenylisoksazol-4- yl]benzensulfonamid NO312461B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14
PCT/US1997/015126 WO1998006708A1 (en) 1996-08-14 1997-08-12 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide

Publications (3)

Publication Number Publication Date
NO990541L true NO990541L (no) 1999-02-05
NO990541D0 NO990541D0 (no) 1999-02-05
NO312461B1 NO312461B1 (no) 2002-05-13

Family

ID=21820280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990541A NO312461B1 (no) 1996-08-14 1999-02-05 Krystallinsk form B av 4-[5-metyl-3-fenylisoksazol-4- yl]benzensulfonamid

Country Status (38)

Country Link
US (2) US6441014B2 (no)
EP (2) EP0920422B1 (no)
JP (2) JP3631763B2 (no)
KR (1) KR100383148B1 (no)
CN (1) CN1205193C (no)
AP (1) AP1055A (no)
AR (1) AR009244A1 (no)
AT (1) ATE228117T1 (no)
AU (1) AU722072B2 (no)
BG (1) BG64259B1 (no)
BR (1) BR9711151A (no)
CA (1) CA2264104A1 (no)
CZ (1) CZ297679B6 (no)
DE (1) DE69717281T2 (no)
DK (1) DK0920422T3 (no)
EA (2) EA003754B1 (no)
EE (1) EE04237B1 (no)
ES (1) ES2188971T3 (no)
GE (1) GEP20022636B (no)
HU (1) HUP0400923A3 (no)
IL (2) IL161224A0 (no)
IS (1) IS1989B (no)
LT (1) LT4551B (no)
LV (1) LV12274B (no)
NO (1) NO312461B1 (no)
NZ (1) NZ334132A (no)
OA (1) OA11298A (no)
PL (1) PL191313B1 (no)
PT (1) PT920422E (no)
RO (1) RO120771B1 (no)
RS (1) RS49671B (no)
SI (1) SI9720059B (no)
SK (1) SK283558B6 (no)
TR (1) TR199900298T2 (no)
TW (1) TW527350B (no)
UA (1) UA52684C2 (no)
WO (1) WO1998006708A1 (no)
ZA (1) ZA977314B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9720059B (sl) * 1996-08-14 2011-11-30 Searle & Co Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
AU1398899A (en) * 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
AU3384200A (en) * 1999-03-01 2000-09-21 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and a selective cox-2 inhibitor drug
IL148019A0 (en) 1999-08-20 2002-09-12 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and an anticonvulsant drug
US6403640B1 (en) * 1999-08-27 2002-06-11 Merck & Co., Inc. Method for treating chronic prostatitis or chronic pelvic pain syndrome
EA008242B1 (ru) 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
DK3168218T3 (en) * 2001-08-15 2019-01-14 Pharmacia & Upjohn Co Llc Crystalline comprising an L-malic acid salt of N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE) METHYL] -2,4 -DIMETHYL-1H-PYRROL-3-CARBOXAMIDE FOR USE AS A MEDICINE
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
US7538126B2 (en) 2003-04-04 2009-05-26 Hetero Drugs Limited Crystalline forms of valdecoxib
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (en) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Form a of valdecoxib suitable for pharmaceutical formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
ATE223390T1 (de) * 1995-02-13 2002-09-15 Searle & Co Substituierte isoxazole zur behandlung von entzündung
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
SI9720059B (sl) * 1996-08-14 2011-11-30 Searle & Co Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida
US7538126B2 (en) * 2003-04-04 2009-05-26 Hetero Drugs Limited Crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Also Published As

Publication number Publication date
LV12274A (lv) 1999-05-20
DE69717281D1 (de) 2003-01-02
YU7499A (sh) 2000-03-21
US6441014B2 (en) 2002-08-27
AP9901458A0 (en) 1999-03-31
TW527350B (en) 2003-04-11
EP0920422A1 (en) 1999-06-09
IS1989B (is) 2005-02-15
EE9900053A (et) 1999-08-16
PL191313B1 (pl) 2006-04-28
EA001472B1 (ru) 2001-04-23
US7135489B2 (en) 2006-11-14
HUP0400923A2 (hu) 2004-08-30
ZA977314B (en) 1998-08-14
KR20000029994A (ko) 2000-05-25
EP1283203A1 (en) 2003-02-12
SK283558B6 (sk) 2003-09-11
SK13699A3 (en) 1999-07-12
ES2188971T3 (es) 2003-07-01
KR100383148B1 (ko) 2003-05-09
JP2000506542A (ja) 2000-05-30
EA003754B1 (ru) 2003-08-28
AP1055A (en) 2002-04-04
BR9711151A (pt) 1999-08-17
JP3631763B2 (ja) 2005-03-23
ATE228117T1 (de) 2002-12-15
AR009244A1 (es) 2000-04-12
DK0920422T3 (da) 2003-03-17
PL331607A1 (en) 1999-08-02
PT920422E (pt) 2003-03-31
BG64259B1 (bg) 2004-07-30
LV12274B (en) 1999-09-20
DE69717281T2 (de) 2003-09-04
US20010003752A1 (en) 2001-06-14
HK1023125A1 (en) 2000-09-01
OA11298A (en) 2003-10-22
RO120771B1 (ro) 2006-07-28
CZ33499A3 (cs) 1999-06-16
UA52684C2 (uk) 2003-01-15
SI9720059A (sl) 1999-12-31
IL128255A (en) 2004-06-20
SI9720059B (sl) 2011-11-30
AU4093697A (en) 1998-03-06
NO312461B1 (no) 2002-05-13
EP0920422B1 (en) 2002-11-20
HUP0400923A3 (en) 2007-11-28
EA200000891A1 (ru) 2001-02-26
CA2264104A1 (en) 1998-02-19
LT99024A (en) 1999-07-26
CN1205193C (zh) 2005-06-08
GEP20022636B (en) 2002-02-25
RS49671B (sr) 2007-11-15
NO990541D0 (no) 1999-02-05
BG103155A (bg) 1999-11-30
NZ334132A (en) 2000-06-23
JP2005015497A (ja) 2005-01-20
WO1998006708A1 (en) 1998-02-19
LT4551B (lt) 1999-10-25
CZ297679B6 (cs) 2007-03-07
EE04237B1 (et) 2004-02-16
IL161224A0 (en) 2004-09-27
TR199900298T2 (xx) 1999-05-21
AU722072B2 (en) 2000-07-20
US20030004200A1 (en) 2003-01-02
IL128255A0 (en) 1999-11-30
EA199900200A1 (ru) 1999-06-24
IS4961A (is) 1999-01-29
CN1233243A (zh) 1999-10-27

Similar Documents

Publication Publication Date Title
NO990541D0 (no) Krystallinsk form av 4-(5-metyl-3-fenylisoksazol-4-yl)benzensulfonamid
NO995852L (no) Ny form av S-omeprazol
ATE408607T1 (de) Substituierte benzensulfonamid-derivate als wirkstoff-vorläufer von cox-2 inhibitoren
DE69631100D1 (de) Ätzung von Nitridkristallen
DE19681287T1 (de) Orale Formulierung von 2-Methylthienobenzodiazepin
DK0946547T3 (da) Hidtil ukendt forbindelsesform
DE69941116D1 (de) G von gdf-8
ID24481A (id) Gastrokinetik monosiklik benzamida dari derivat-3-atau-tersubstitusi 4-(aminometil)-piperidin
PT907650E (pt) N-¬4-(heteroarilmetil)fenil|heteroarilaminasc
NO964950D0 (no) Krystallinsk hydroklorid av (R)-(-)-2-æN-[4-1,1-dioksido-3-okso-2,3-dihydrobenzisotiazol-2-yl)-butylÅ-aminometylå-chroman
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
DE69802726D1 (de) Abscheidung von Titannitridfilme
DE69935165D1 (de) Herstellung von polyolefin
FI956015L (fi) 5-asyyli-1,4-dihydropyridiinien käyttö
NO20010553L (no) Krystallinske former av osanetant
NO992268D0 (no) N-bundne sulfonamider av heterocykliske tioestere
NO983784L (no) Fremgangsmåter for fremstilling av bifenyl-isoksasolsulfonamider
DK0810216T3 (da) Derivater af 10,11-dihydro-10-oxo-5H-dibenz/b/,f/azepin-5-carboxamid
NO991148D0 (no) Fremstilling av 1-butyl-4-piperidinyl-metylamin
EE200400073A (et) 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm ja selle kasutamine
NO20004583D0 (no) Krystallinsk form av paroxetine
NO953272D0 (no) Kombinasjoner av retrovirale inhibitorer
SE9702853D0 (sv) Fasning av mynt
SE9600037D0 (sv) Modifiering av cement
FI3045U1 (fi) Säilytysrasiasarja